Core Viewpoint - The company has received approval from the China Securities Regulatory Commission for the full circulation of approximately 182.6 million unlisted shares, allowing them to convert to H-shares and be listed [1] Group 1: Regulatory Approval - The company has completed the filing for the conversion of about 182.6 million unlisted shares into H-shares for full circulation [1] - If the conversion and listing are not completed within 12 months from the date of issuance, the company will need to update its filing materials with the China Securities Regulatory Commission to proceed [1] Group 2: Strategic Development - The company showcased its "Globalization 2.0" strategy at the JPM 2026 conference, outlining its future innovation pipeline and development plans [1] - Over the next five years, the company anticipates more than 40 new clinical research applications to be approved [1] - By 2030, the company expects to have over 20 products launched globally, with 15 of them likely entering the European and American markets [1] Group 3: Product Pipeline and Market Focus - The company plans to commercialize more Antibody-Drug Conjugates (ADCs), bispecific antibodies, and T-cell engagers (TCEs) [1] - The therapeutic areas targeted include oncology, autoimmune diseases, metabolism, and central nervous system disorders [1] Group 4: Financial Performance - As of January 16, the company's stock has increased by 19.63% year-to-date and has risen by 194.18% over the past 250 days [1] - The total market capitalization of the company is HKD 37.1 billion [1]

Core Viewpoint - The company has completed a Phase I clinical trial for its "house dust mite film agent," demonstrating good safety and tolerability in adult patients with dust mite allergic rhinitis in China [1] Group 1: Clinical Trial Results - The clinical trial was randomized, double-blind, placebo-controlled, and involved dose escalation [1] - Safety analysis indicated that all maintenance dose groups (150BU-2700BU) showed good safety, with adverse events classified as grade 1-2, and no serious adverse events or events leading to withdrawal were reported [1] Group 2: Immune Response Indication - Exploratory analysis revealed an upward trend in specific IgE and IgG4 levels related to house dust mites in the treatment groups compared to baseline, suggesting that continuous administration for 28 days may have induced an immune response [1]

在满足许可协议约定的条款下，众生睿创将获得首付款及里程碑付款总金额为人民币100,000万元，包 括首付款人民币20,000万元、开发和销售里程碑付款最高合计人民币80,000万元，后续产品上市后有权 获得许可产品净销售额双位数的销售提成。 许可产品RAY1225注射液是众生睿创研发的、具有全球自主知识产权的创新结构多肽药物，具有GLP-1 受体和GIP受体双重激动活性，得益于优异的药代动力学特性，具备每两周注射一次的超长效药物潜 力。目前，RAY1225注射液用于治疗中国肥胖/超重患者的安全性和有效性III期临床试验 格隆汇1月16日丨众生药业(002317.SZ)公布，控股子公司广东众生睿创生物科技有限公司（简称"众生 睿创"）与齐鲁制药有限公司（简称"齐鲁制药"）于2026年1月16日签署《许可协议》，众生睿创授权齐 鲁制药在中国地区（包括中国大陆、香港、澳门、台湾，统称"许可地区"）内对RAY1225注射液（简 称"许可产品"）进行生产与商业化销售，众生睿创保留许可知识产权的全部权利、权属和权益，在许可 产品获得药品监管部门上市注册批准后，众生睿创为药品上市许可持有人（MAH）。同时，众生睿创 仍然拥 ...

Core Viewpoint - The company, Recbio, anticipates a significant decline in revenue and an increase in net losses for the year 2025, primarily due to industry policy changes and increased R&D investments [1] Financial Performance - Expected revenue for 2025 is projected to be between 400 million to 420 million yuan, representing a year-on-year decrease of 17.79% to 21.71% [1] - The net profit attributable to the parent company is forecasted to be between -210 million to -230 million yuan, indicating an increase in losses by 9.94% to 20.42% [1] - The non-recurring net profit is expected to range from -250 million to -270 million yuan [1] Factors Influencing Performance - The performance changes are mainly attributed to industry policies such as centralized procurement and tax policy adjustments, as well as impairment losses on operating assets [1] - Increased R&D investments following the capital increase in Shunjing Pharmaceutical and the consolidation of financial statements are also contributing factors [1] - The company has seen expanded investment losses due to increased R&D expenditures in joint ventures [1]

Core Viewpoint - The company, 热景生物 (Hotgen Biotech), is expected to experience a significant decline in revenue and an increase in net losses for the fiscal year 2025 compared to the previous year [1] Financial Performance - The projected revenue for 2025 is estimated to be between 400 million yuan and 420 million yuan, representing a year-on-year decrease of 17.79% to 21.71% [1] - The expected net profit attributable to the parent company for 2025 is forecasted to be between -210 million yuan and -230 million yuan, indicating an increase in losses of 9.94% to 20.42% compared to the previous year [1] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, is anticipated to be between -250 million yuan and -270 million yuan for 2025 [1]

Core Viewpoint - The company has received a notification from the China Securities Regulatory Commission (CSRC) regarding the registration of its H-share full circulation plan for approximately 182.6 million unlisted shares held by certain shareholders [1] Group 1 - The company has completed the filing for H-share full circulation with the CSRC [1] - The filing involves a total of approximately 182.6 million shares [1] - If the company does not complete the H-share full circulation conversion and listing within 12 months from the date of the notification, it must update the filing materials with the CSRC [1]

Core Viewpoint - The resignation of independent director Hu Yuntong from the board of Chongqing Zhixiang Jintai Biopharmaceutical Co., Ltd. has been officially announced due to work-related reasons [1] Company Summary - Hu Yuntong has submitted a written resignation report to the board, indicating his intention to resign from his position as an independent director of the company's second board [1] - Following the resignation, Hu Yuntong will no longer hold any position within the company [1]

Group 1 - The company announced on January 16 that it will hold its 15th meeting of the second board of directors on January 15, 2026, to review the proposal for using idle self-owned funds to purchase financial products [1] - The total amount approved for investment in financial products is up to RMB 400 million, which includes the principal [1] - The financial products targeted for investment are low to medium risk with high safety and liquidity, including but not limited to agreed deposits, seven-day notice deposits, structured deposits, large certificates of deposit, income certificates, bond investments, money market fund investments, and entrusted financial management [1] Group 2 - The investment products will have a maturity period of no more than 12 months, and the resolution is valid for 12 months from the date of approval by the board of directors [1] - Within the approved amount and time frame, the company can use the funds in a rolling manner [1]

Group 1 - The company RenDu Bio announced that its second board meeting of the 15th session will be held on January 15, 2026, to review the proposal regarding expected daily related transactions for the year 2026 [1] Group 2 - The silver market has seen a significant increase, with prices rising over 80% in the last 50 days, indicating a potential peak in the precious metals bull market [1]

Core Viewpoint - Chuang'er Bio has terminated its IPO counseling due to unresolved shareholder equity freeze issues, marking a significant setback in its long and tumultuous journey towards public listing [1][5][10]. Company Overview - Founded in 2002, Chuang'er Bio specializes in the research, development, and production of active collagen biomedical materials, and is recognized as a high-tech enterprise in China [4]. - The company launched its core brand "Chuangfukang," which held an 8% market share in the Chinese patch-type medical skin repair dressing market in 2019, ranking second in the industry [1][16]. Financial Performance - In the first half of 2025, Chuang'er Bio reported a revenue of 214 million yuan, a year-on-year increase of 16.98%, but its net profit attributable to shareholders dropped significantly by 55.99% to 13.21 million yuan [4][12]. - The company's revenue structure shows that collagen products accounted for 87.83% of total revenue, indicating its reliance on this segment [4][13]. IPO Journey - Chuang'er Bio's IPO attempts have been fraught with challenges, including two failed attempts to list on the Sci-Tech Innovation Board and the Beijing Stock Exchange due to financial performance issues and shareholder equity freezes [10][14]. - The company’s second-largest shareholder, Ding Yumei, has had her shares frozen, which has been a critical factor in the termination of the IPO process [5][8]. Industry Context - The tightening of regulatory policies in the "medical device" sector has significantly impacted the growth of companies like Chuang'er Bio, which was once a leader in the collagen dressing market [16][17]. - Competitors such as Jinjian Bio and Fuhua have successfully entered the capital market and expanded their technological and market advantages, leaving Chuang'er Bio at a disadvantage [17][19]. Market Dynamics - The collagen product market is becoming increasingly competitive, with new entrants intensifying the pressure on established players like Chuang'er Bio [18]. - The shift towards restructured collagen products is becoming a market and technological trend, benefiting companies that adapt to these changes [19].